Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 547 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ‘A significant step forwards’ – treating patients with advanced biliary tract... March 30, 2021 Health of Gut Microbes May Affect Survival after Stem Cell Transplant March 25, 2020 When You Have to Make Decisions for a Loved One With... November 9, 2020 Axicabtagene Ciloleucel Results in High Response Rates and Durable Remissions as... October 5, 2023 Load more HOT NEWS Tucatinib and Trastuzumab Combination Approved for Advanced Colorectal Cancer What Do “Health Equity” and “Quality Care” Mean in Cancer Care? FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or... Fourth Vaccine Dose Increases in Humoral Immunity Against Omicron Variants in...
